Dry Eye Disease Affects Around 50M Americans, OKYO Pharma’s Candidate Shows Safety In Mid-Stage Study
OKYO Pharma Limited (NASDAQ: OKYO) announced that its first drug candidate, OK-101, presently in a 240-patient phase 2 trial in patients with dry eye disease (DED) is currently showing a positive safety profile in